WebJan 6, 2024 · Alumis, formerly Esker Therapeutics, a precision immunology company backed by Foresite Capital and incubated by Foresite Labs that is reimagining the discovery, development and treatment of autoimmune disorders, today announced the completion of a $200 million financing led by AyurMaya, an affiliate of Matrix Capital Management, and … WebEsker Therapeutics is a precision medicines company with the mission to transform the lives of patients with autoimmune diseases. Our pipeline is led by ESK-001, a potentially …
Alumis - Overview, News & Competitors ZoomInfo.com
WebMay 7, 2024 · Pharmaceuticals Esker Therapeutics has launched with $70 million in series A financing from the investment firm Foresite Capital to develop drugs for autoimmune diseases. The San Francisco–based start-up’s lead program is an inhibitor of a tyrosine kinase called TYK2. It’s in a Phase 1 clinical trial as a treatment for psoriasis. WebFounded Date 2024. Founders June Lee. Operating Status Active. Last Funding Type Series B. Also Known As Esker Therapeutics. Legal Name ALUMIS INC. Company Type For Profit. Contact Email … the beatles instruments played
Esker Therapeutics Trademark - Fl2024-001, Inc. - San Francisco, …
WebFind company research, competitor information, contact details & financial data for Esker Therapeutics, Inc. of San Francisco, CA. Get the latest business insights from Dun & … WebJan 6, 2024 · Precision Immunology Biotech Rebrands and Scores $200 Million Published: Jan 06, 2024 By Mark Terry Alumis, formerly Esker Therapeutics, a San Francisco-based biotech company, closed on a $200 million Series B financing round. The company is backed by Foresite Capital and incubated by Foresite Labs. WebSince 2010, Esker shares have been listed on Euronext Growth (formerly Alternext) market for growth companies managed by Euronext Paris. ESKER by TradingView Annual reports the beatles instrumental songs